Anti-ENO2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-3419-FY)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-ENO2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • ENO2
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 2026
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-3419-FY 5E2 Mouse Guinea Pig IgG2a
DMAb-3421-FY AT17D10 Mouse Human IgG2b, κ Recombinant human NSE purified from E.coli. Immunogen type: Recombinant protein.
DMAb-3422-FY BBS-NC-VI-H14 Mouse IgG1 Purified Human gamma-gamma Enolase
DMAb-3423-FY NSEP2 Mouse Human IgG1, κ Ovalbumin-conjugated synthetic peptides corresponding to human NSE amino acid sequence: TGDQLGALYQDFVRD
DMAb-3463CQ BA0108 Rabbit IgG Human NSE aa 200-350
DMAb-3464CQ ENO2/1462 Mouse IgG2b Human NSE aa 416-433
DMAb-3465CQ SPM347 Mouse Human IgG2b Human NSE aa 416-433
DMAb-3466CQ ENO2/1375 Mouse IgG2b Synthetic peptide within Human NSE aa 416-433
DMAb-3467CQ BA0013 Rabbit Human IgG Human REEP5 aa 150 to the C-terminus
DMAb-3468CQ BA0239 Rabbit IgG Synthetic peptide from residues in human NSE
DMAb-3470CQ 37E4 Mouse IgG1 Recombinant full length protein
DMAb-3471CQ 85F11 Mouse IgG2a, κ Recombinant full length protein
DMAb-3472CQ BA0240 Rabbit IgG Synthetic peptide
DMAb-3473CQ NSE-P1 Mouse Human IgG1 C terminal amino acids 416-433 of NSE

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-ENO2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-3419-FY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.